OBJECTIVE: The prevalence of both low testosterone levels and depression increases with age. Currently, there is no consensus regarding the existence of an association. Our study analyses the cross-sectional association of testosterone levels with depressive symptoms and its prospective association with the development of incident depressive symptoms. DESIGN: Longitudinal population-based study; based on the data of the Longitudinal Aging Study Amsterdam (LASA) including 608 men aged >or=65 years (median age 75.6 years). MEASUREMENTS: Linear and logistic regression between total and free testosterone levels and depressive symptoms as measured by the Center of Epidemiologic Studies Depression (CES-D) scale, taking into account medical and lifestyle factors. Cox Proportional Hazards model was used to assess incident depressive symptoms. RESULTS: Unadjusted linear regression between square-root transformed CES-D scores and free testosterone levels showed a significant inverse association as a continuous variable (beta = -0.10, P < 0.05), lowest quartile compared to highest (beta = 0.12, P < 0.05) and with a threshold value of 170 pmol/l (beta = 0.13, P < 0.05). The results remained significant for the group below threshold after adjustment for all confounders (beta = 0.09, P < 0.05). Cox Proportional Hazards Model showed a decreased risk for incident depressive symptoms for men with higher free testosterone levels [HR = 0.997 CI (0.995-1.000)]. Men with the threshold value below 220 pmol/l were at increased risk of incident depressive symptoms [HR = 1.989 CI (1.173-3.374)]. CONCLUSIONS: Free testosterone levels below 170 pmol/l are associated with depressive symptoms, while free testosterone levels below 220 pmol/l (lowest quintile of our population) predict the onset of depressive symptoms.
OBJECTIVE: The prevalence of both low testosterone levels and depression increases with age. Currently, there is no consensus regarding the existence of an association. Our study analyses the cross-sectional association of testosterone levels with depressive symptoms and its prospective association with the development of incident depressive symptoms. DESIGN: Longitudinal population-based study; based on the data of the Longitudinal Aging Study Amsterdam (LASA) including 608 men aged >or=65 years (median age 75.6 years). MEASUREMENTS: Linear and logistic regression between total and free testosterone levels and depressive symptoms as measured by the Center of Epidemiologic Studies Depression (CES-D) scale, taking into account medical and lifestyle factors. Cox Proportional Hazards model was used to assess incident depressive symptoms. RESULTS: Unadjusted linear regression between square-root transformed CES-D scores and free testosterone levels showed a significant inverse association as a continuous variable (beta = -0.10, P < 0.05), lowest quartile compared to highest (beta = 0.12, P < 0.05) and with a threshold value of 170 pmol/l (beta = 0.13, P < 0.05). The results remained significant for the group below threshold after adjustment for all confounders (beta = 0.09, P < 0.05). Cox Proportional Hazards Model showed a decreased risk for incident depressive symptoms for men with higher free testosterone levels [HR = 0.997 CI (0.995-1.000)]. Men with the threshold value below 220 pmol/l were at increased risk of incident depressive symptoms [HR = 1.989 CI (1.173-3.374)]. CONCLUSIONS: Free testosterone levels below 170 pmol/l are associated with depressive symptoms, while free testosterone levels below 220 pmol/l (lowest quintile of our population) predict the onset of depressive symptoms.
Authors: Monique S Tanna; Arthur Schwartzbard; Jeffery S Berger; Joseph Alukal; Howard Weintraub Journal: Curr Atheroscler Rep Date: 2015-03 Impact factor: 5.113
Authors: Samuel Y S Wong; Jason C Leung; Timothy Kwok; Claes Ohlsson; Liesbeth Vandenput; Ping C Leung; Jean Woo Journal: Asian J Androl Date: 2011-08-29 Impact factor: 3.285
Authors: Ilmari Määttänen; Kia Gluschkoff; Kaisla Komulainen; Jaakko Airaksinen; Kateryna Savelieva; Regina García-Velázquez; Markus Jokela Journal: Compr Psychoneuroendocrinol Date: 2021-03-10
Authors: Catherine Kim; Elizabeth Barrett-Connor; Vanita R Aroda; Kieren J Mather; Costas A Christophi; Edward S Horton; Xavier Pi-Sunyer; George A Bray; Fernand Labrie; Sherita Hill Golden Journal: Psychoneuroendocrinology Date: 2016-06-15 Impact factor: 4.905
Authors: Matthew S Panizzon; Richard Hauger; Kristen C Jacobson; Lindon J Eaves; Timothy P York; Elizabeth Prom-Wormley; Michael D Grant; Michael J Lyons; Ruth McKenzie; Sally P Mendoza; Hong Xian; Carol E Franz; William S Kremen Journal: Psychoneuroendocrinology Date: 2013-04-29 Impact factor: 4.905
Authors: Stephanie Rodgers; Martin Grosse Holtforth; Michael P Hengartner; Mario Müller; Aleksandra A Aleksandrowicz; Wulf Rössler; Vladeta Ajdacic-Gross Journal: Front Psychiatry Date: 2015-05-04 Impact factor: 4.157
Authors: Hanna Kische; Stefan Gross; Henri Wallaschofski; Hans Jörgen Grabe; Henry Völzke; Matthias Nauck; Robin Haring Journal: PLoS One Date: 2017-05-12 Impact factor: 3.240
Authors: Amy C Reynolds; Jillian Dorrian; Peter Y Liu; Hans P A Van Dongen; Gary A Wittert; Lee J Harmer; Siobhan Banks Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240